Cargando…

A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer

SIMPLE SUMMARY: Most ovarian cancer patients initially show a response to primary treatments, but the development of refractory disease is a major problem. Currently, there are no blood-based prognostic biomarkers, and the prognosis of a patient is determined by the International Federation of Gynec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salminen, Liina, Braicu, Elena Ioana, Lääperi, Mitja, Jylhä, Antti, Oksa, Sinikka, Hietanen, Sakari, Sehouli, Jalid, Kulbe, Hagen, du Bois, Andreas, Mahner, Sven, Harter, Philipp, Carpén, Olli, Huhtinen, Kaisa, Hynninen, Johanna, Hilvo, Mika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067677/ https://www.ncbi.nlm.nih.gov/pubmed/33917079 http://dx.doi.org/10.3390/cancers13081764

Ejemplares similares

Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism
por: Niemi, Riikka Johanna, et al.
Publicado: (2018)

Absolute and relative risk prediction in cardiovascular primary prevention with a modified SCORE chart incorporating ceramide-phospholipid risk score and diabetes mellitus
por: Hilvo, Mika, et al.
Publicado: (2021)

Extensive mutational ctDNA profiles reflect High-grade serous cancer tumors and reveal emerging mutations at recurrence
por: Marchi, Giovanni, et al.
Publicado: (2023)

Prospective Longitudinal ctDNA Workflow Reveals Clinically Actionable Alterations in Ovarian Cancer
por: Oikkonen, Jaana, et al.
Publicado: (2019)

QuantISH: RNA in situ hybridization image analysis framework for quantifying cell type-specific target RNA expression and variability
por: Jamalzadeh, Sanaz, et al.
Publicado: (2022)

In Silico Analysis Predicts Nuclear Factors NR2F6 and YAP1 as Mesenchymal Subtype-Specific Therapeutic Targets for Ovarian Cancer Patients
por: Kassuhn, Wanja, et al.
Publicado: (2023)

Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality
por: Jukonen, Joonas, et al.
Publicado: (2021)

FUNGI: FUsioN Gene Integration toolset
por: Cervera, Alejandra, et al.
Publicado: (2021)

PRISM: recovering cell-type-specific expression profiles from individual composite RNA-seq samples
por: Häkkinen, Antti, et al.
Publicado: (2021)

Fertility-Sparing Surgery in Early Epithelial Ovarian Cancer: A Viable Option?
por: Fotopoulou, Christina, et al.
Publicado: (2012)

Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer
por: Zhang, Kaiyang, et al.
Publicado: (2022)

Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer—Impact for Diagnosis and Treatment Monitoring
por: Braicu, Elena Ioana, et al.
Publicado: (2021)

Network-guided identification of cancer-selective combinatorial therapies in ovarian cancer
por: He, Liye, et al.
Publicado: (2021)

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
por: Darb-Esfahani, Silvia, et al.
Publicado: (2015)

qSNE: quadratic rate t-SNE optimizer with automatic parameter tuning for large datasets
por: Häkkinen, Antti, et al.
Publicado: (2020)

Agile workflow for interactive analysis of mass cytometry data
por: Casado, Julia, et al.
Publicado: (2020)

Discovery and Validation of Novel Biomarkers for Detection of Epithelial Ovarian Cancer
por: Kulbe, Hagen, et al.
Publicado: (2019)

High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism
por: Braicu, Elena Ioana, et al.
Publicado: (2017)

Discovery of Prognostic Markers for Early-Stage High-Grade Serous Ovarian Cancer by Maldi-Imaging
por: Kulbe, Hagen, et al.
Publicado: (2020)

Chondroitin Sulfate Disaccharides, a Serum Marker for Primary Serous Epithelial Ovarian Cancer
por: Biskup, Karina, et al.
Publicado: (2021)

Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group
por: Trillsch, Fabian, et al.
Publicado: (2021)

Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cells
por: Kulbe, Hagen, et al.
Publicado: (2016)

Low Expression of RGS2 Promotes Poor Prognosis in High-Grade Serous Ovarian Cancer
por: Ihlow, Jana, et al.
Publicado: (2022)

HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVCAD Consortium
por: Braicu, Elena Ioana, et al.
Publicado: (2014)

The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium
por: Obermayr, Eva, et al.
Publicado: (2021)

Sialic Acid Linkage Analysis Refines the Diagnosis of Ovarian Cancer
por: Dědová, Tereza, et al.
Publicado: (2019)

Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis
por: Baum, Joanna, et al.
Publicado: (2023)

Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer
por: Woopen, Hannah, et al.
Publicado: (2014)

Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer—A Study of the OVCAD Consortium
por: Obermayr, Eva, et al.
Publicado: (2021)

Stable expansion of high‐grade serous ovarian cancer organoids requires a low‐Wnt environment
por: Hoffmann, Karen, et al.
Publicado: (2020)

Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis
por: Cherif, Soumia, et al.
Publicado: (2021)

Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
por: Pikkusaari, Sanna, et al.
Publicado: (2023)

Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer
por: Mungenast, Felicitas, et al.
Publicado: (2017)

The Serum Glycome to Discriminate between Early-Stage Epithelial Ovarian Cancer and Benign Ovarian Diseases
por: Biskup, Karina, et al.
Publicado: (2014)

Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test)
por: Kischkel, Frank Christian, et al.
Publicado: (2017)

Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer()
por: Stanske, Mandy, et al.
Publicado: (2018)

Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
por: Glajzer, Jacek, et al.
Publicado: (2022)

Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma
por: Marchenko, Sofya, et al.
Publicado: (2022)

Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium
por: Aust, Stefanie, et al.
Publicado: (2014)

Author Correction: Virtual clinical trials identify effective combination therapies in ovarian cancer
por: Kozłowska, Emilia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ne43kj1liskkrtkanrd3ksgo37